dismiss

Clean Sweep Live Auction on Thur. March 28th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

Apple study suggests wearable technology may be useful in detecting atrial fibrillation May assist in stroke and hospitalization prevention

Echocardiogram should play role in patient selection for transcatheter mitral valve repair, says study New study highlighted at ACC

FDA gives green light for smallest, slimmest 3T CRM devices Extended battery lives, greater diagnostic and therapeutic capabilities

Level Ex releases interventional cardiac video game, Cardio Ex Over 35 levels that test cognitive, spatial reasoning and decision-making skills

Siemens to unveil its SOMATOM go.Top Cardiovascular Edition CT at ACC 19 Ideal for the cardiovascular outpatient setting

FDA approves Sonavex's EchoSure system Monitors blood flow following surgical procedures

Siemens unveils Artis icono biplane angio system at ECR Enables diagnostics and treatment to take place in same lab, improved 2D and 3D capabilities

Personalized cardiac test could eliminate unnecessary catheterizations Examines flow of blood with AI and CT

Noninvasive approach for imaging carotid artery shows promise Enables risk assessment for cardiovascular disease

John D. Zehren Endologix appoints chief commercial officer

Boston Scientific acquires Millipede

Boston Scientific to acquire shares of Millipede for $325 million

by John R. Fischer , Staff Reporter
Boston Scientific Corporation has said "yes" to the option of acquiring complete ownership of Millipede, a private company focused on developing the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation (MR).

Having agreed to an investment and acquisition option back in January 2018, the Massachusetts-based manufacturer acquired $90 million worth of outstanding and newly issued shares, and will now take the remaining ones for an additional $325 million, with a further $125 million to be paid upon the completion of a commercial milestone. Its decision to do so follows the successful completion of a first-in-human clinical trial using the system.

Story Continues Below Advertisement

Has exclusive distribution agreement with DDD to sell new Camera systems

UMRi provides the very best new & refurbished gamma cameras, quality parts &repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510



"We are very satisfied with the early results of our clinical program and are excited to see this technology further leveraged by Boston Scientific to expand the mitral repair solutions for patients around the world," said Randy Lashinski, co-founder and CEO of Millipede, in a statement.

Estimated to reach $1 billion by 2021, the majority of the drive behind the transcatheter mitral repair and replacement market consists of repair procedures.

Administered through a transcatheter-transseptal delivery system, the Millipede IRIS annuloplasty ring can repair and reduce the size of a dilated mitral annulus in standard surgical fashion. It consists of a complete ring that is used as a standalone device, or in combination with other technologies in patients with severe MR, and is highly customizable to a patient’s anatomy and disease state. In addition, the solution is repositionable and retrievable, promoting a high-quality outcome.

The option to acquire the remaining shares was available to Boston Scientific at any time prior to and after the completion of a first-in-human clinical study that met certain parameters. Millipede itself also had the option to compel Boston Scientific to acquire the rest of the shares following the completion of the trial.

The news further builds upon the progress and resources obtained by Boston Scientific over the last year through its many acquisitions which include VENITI, the privately-held maker of the Vici Venous Stent, for $160 million; Claret Medical, the producer of the Sentinel Cerebral Embolic Protection System for TAVR operations on patients at risk of stroke; nVision Medical Corporation, a private enterprise focused on women's health; and Securus Medical Group, a company that has developed a thermal monitoring system for the continuous measurement of esophageal temperature.
  Pages: 1 - 2 >>

Cardiology Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED